Z Gastroenterol 2020; 58(03): e71
DOI: 10.1055/a-1143-8420
Erratum

Adverse effects of PD-1 targeted immunotherapy in NAFLD-triggered HCC

Authors

  • D Pfister

    1   DKFZ, F180-Chronic Inflammation and Cancer, Heidelberg, Germany
  • N Nunez

    2   UZH, Institute of Experimental Immunology, Zurich, Switzerland
  • A Sinha

    3   MPI of Biochemistry, Experimental Systems Immunology, Martinsried, Germany
  • A Weiner

    4   Weizmann Institute of Science, Department of Immunology, Rehovot, Israel
  • A Deczkowska

    4   Weizmann Institute of Science, Department of Immunology, Rehovot, Israel
  • M Pinter

    5   Medical University of Vienna, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Vienna, Austria
  • O Govaere

    6   The Medical School, Newcastle University, Institute of Cellular Medicine, Newcastle, United Kingdom
  • F Müller

    1   DKFZ, F180-Chronic Inflammation and Cancer, Heidelberg, Germany
  • Q M Anstee

    6   The Medical School, Newcastle University, Institute of Cellular Medicine, Newcastle, United Kingdom
  • T Entgleitner

    7   TUM, Department of Medicine II, Munich, Germany
  • R Rad

    7   TUM, Department of Medicine II, Munich, Germany
  • R Pinyol

    8   Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clínic, Universitat de Barcelona, Liver Cancer Translational Research Laboratory, Barcelona, Spain
  • S Torrecilla

    8   Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clínic, Universitat de Barcelona, Liver Cancer Translational Research Laboratory, Barcelona, Spain
  • M Dudek

    9   TUM, Institute of Molecular Immunology and Experimental Oncology, Munich, Germany
  • P Knolle

    9   TUM, Institute of Molecular Immunology and Experimental Oncology, Munich, Germany
  • A Weber

    10   University Zurich, Institute for Molecular Pathology, Zurich, Switzerland
  • D Lengenhagger

    10   University Zurich, Institute for Molecular Pathology, Zurich, Switzerland
  • J M Llovet

    8   Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clínic, Universitat de Barcelona, Liver Cancer Translational Research Laboratory, Barcelona, Spain
  • I Amit

    4   Weizmann Institute of Science, Department of Immunology, Rehovot, Israel
  • F Meissner

    3   MPI of Biochemistry, Experimental Systems Immunology, Martinsried, Germany
  • B Becher

    2   UZH, Institute of Experimental Immunology, Zurich, Switzerland
  • M Heikenwälder

    1   DKFZ, F180-Chronic Inflammation and Cancer, Heidelberg, Germany
Preview


Publication History

Article published online:
24 March 2020

© Georg Thieme Verlag KG
Stuttgart · New York